AdCella and SHcell hold first JDC meeting
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The meeting identified opportunities to accelerate development timelines and reduce regulatory risks associated with the CAR-T therapy. Key outcomes include the potential to expedite manufacturing transfer to Australia and a refined engagement strategy with the US FDA. AdCella plans to optimize manufacturing processes and conduct final toxicology studies in preparation for clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- New AD-214 patent granted
- AdCella expands clinical advisory board
- AdCella Clinical Advisory Board convened
- Half Yearly Report and Accounts
- Quarterly Appendix 4C and Activities Report
Later from AdAlta
- BZDS1901 clinical update
- Automated cell therapy manufacturing MoU
- BZDS1901 manufacturing agreement
- $2.5m placement
- Regulatory advisors appointed for BZDS1901
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta